SOURCE: AtheroNova Inc.

AtheroNova Inc.

February 14, 2011 08:45 ET

AtheroNova Inc. Atherosclerotic Plaque Regression Study Commences at Cedars-Sinai Heart Institute

IRVINE, CA--(Marketwire - February 14, 2011) - AtheroNova Inc. (OTCBB: AHRO) ("AtheroNova"), a biotech company focused on the research and development of compounds to regress atherosclerotic plaque, announced that the Company's second phase pre-clinical laboratory study has commenced at the Cedars-Sinai Heart Institute's Division of Cardiology and Oppenheimer Atherosclerosis Research Center under the overall direction of P.K. Shah, MD. 

The protocol for the study is designed to validate the results of the Company's initial pre-clinical study demonstrating the study group having 95 percent less arterial plaque compared to the control group. The study is expected to be completed within approximately six months.

"We are pleased to announce that our second round preclinical study at the Cedars-Sinai Heart Institute has begun," stated Thomas W. Gardner, CEO of AtheroNova. "This is a significant milestone for the Company as we work towards our goal of developing innovative new treatments for lipid related diseases. The completion of these second round studies should wrap up the preclinical phase of our development program."

"Following the completion of the second round studies we expect to submit an atherosclerotic plaque regression Investigational New Drug Application (IND) and then launch human trials," added Mr. Gardner.

About AtheroNova

AtheroNova, through its wholly-owned subsidiary, AtheroNova Operations, Inc., is a development stage company currently researching novel patents-pending applications of certain natural compounds to regress atherosclerotic plaque deposits, a process called delipidization. The Company has entered into a research agreement for the second phase of its laboratory study at the Cedars-Sinai Heart Institute's Division of Cardiology to validate the findings of its initial study and prepare for human trials. AtheroNova plans to develop multiple applications for its compounds, to be used in pharmaceutical grade products for the treatment of atherosclerosis.

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the commencement of the second animal trial and preparations for human trials, and the development of applications for AtheroNova's compounds. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in AtheroNova's filings with the United States Securities and Exchange Commission. AtheroNova undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information

  • Company contact:
    Thomas Gardner
    Chief Executive Officer

    Or

    Mark Selawski
    Chief Financial Officer
    (949) 476-1100

    Investor Contact:
    Leon Hamerling
    Investor Media Group
    (877) 725-2500